ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-OR128

Probiotic Dietary Supplementation in Hemodialysis Patients: A Double-blind, Randomized, Placebo-Controlled Trial

Session Information

Category: Health Maintenance, Nutrition, and Metabolism

  • 1302 Health Maintenance, Nutrition, and Metabolism: Clinical

Authors

  • Liu, Sixiu, First Affiliated Hospital of Medicine School, Xi'an Jiaotong University, Xi'an, China
  • Jiang, Hongli, First Affiliated Hospital of Medicine School, Xi'an Jiaotong University, Xi'an, China
Background

Recent studies have highlighted that gut microbiota is a key origin of uremic retention solutes in patients with chronic kidney disease, and is involved in triggering systemic microinflammation. The objective of this study was to evaluate the effects of probiotics on the gut microbiota profile and inflammatory markers in hemodialysis (HD) patients.

Methods

This was a randomized, double-blind, placebo-controlled study. Fifty HD patients were assigned to receive 1 of 2 treatments: probiotic (Pro0,n = 25; Enterococcus faecalis, Lactobacillus acidophilus, Bifidobacterium longum, 4 capsules each, twice daily, totally containing 30 billion colony-forming units per day) or placebo (PL0,n = 25) daily for 6 months. Blood samples and feces samples were collected at baseline and after intervention. The gut microbiota profile, inflammatory markers (IL-6, TNF-α and hs-CRP) and endotoxin were assessed.(Trial registration number NCT02929225.)

Results

Twenty-three patients remained in the probiotic group(Pro2) and 22 in the placebo group(PL2). Compared with the placebo group, probiotics did not induce major changes in the faecal microbiome. The alpha and beta diversity of gut microbiota in probiotic group were not significantly different from placebo group(Fig.1(A)and(B)). However, according to the Linear discriminant analysis coupled with effect size measurements (LEfSe) further identified four bacterial families that significantly changed. Particularly, Family Enterococcaceae was increased, while Ruminococcaceae was reduced in probiotic group. In addition, the plasma levels of inflammatory markers and endotoxin were not affected by probiotics.

Conclusion

In HD patients, probiotics did not significantly induce major alterations in the fecal microbiome but several specific bacteria relative abundance were restored.

Funding

  • Government Support - Non-U.S.